Skip to content

Released Nov 14, 2023, after the close

10-Q filed Nov 14, 2023, 45 days after period end · 0001493152-23-041124

Q2 2024 · 10-Q
Revenue$14.16M+64.9% vs Q2 2023+57.7% vs Q1 2024
Net Income$14.93M+885.7% vs Q2 2023+1,208.0% vs Q1 2024
EPS Diluted$0.01— vs Q2 2023no prior Q1 2024 on file
Gross Profit$6,447,079+68.6%
Operating Income$1,925,505+78.1%
Operating Cash Flowderived-$235,938N/M
Margins · derived
Gross margin45.5%+1.0 pt vs Q2 2023
Operating margin13.6%+1.0 pt vs Q2 2023
Net margin105.5%+87.8 pt vs Q2 2023

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$14.16M$8.59M$8.56M$7.40M
Net Income$14.93M$1.52M$1.80M$2.48M
EPS Diluted$0.01$0.00$0.00$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR